Summit X LLC boosted its holdings in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) by 36.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 198,163 shares of the company's stock after purchasing an additional 52,508 shares during the quarter. Summit X LLC owned approximately 0.16% of Mesoblast worth $2,473,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in MESO. Bank of America Corp DE increased its holdings in shares of Mesoblast by 1,503.3% in the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after acquiring an additional 272,595 shares during the last quarter. Oaktree Capital Management LP acquired a new position in Mesoblast during the 4th quarter valued at approximately $3,556,000. GAMMA Investing LLC boosted its position in Mesoblast by 1,174.2% during the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock valued at $1,067,000 after purchasing an additional 78,802 shares during the period. Oaktree Fund Advisors LLC acquired a new position in Mesoblast during the 4th quarter valued at approximately $949,000. Finally, Cubist Systematic Strategies LLC boosted its position in Mesoblast by 241.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 35,191 shares of the company's stock valued at $697,000 after purchasing an additional 24,870 shares during the period. 1.43% of the stock is currently owned by institutional investors.
Mesoblast Stock Performance
NASDAQ:MESO traded up $0.99 during midday trading on Thursday, reaching $12.34. 498,344 shares of the company traded hands, compared to its average volume of 278,066. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 0.22. Mesoblast Limited has a twelve month low of $5.78 and a twelve month high of $22.00. The company has a fifty day moving average price of $11.21 and a 200 day moving average price of $13.68.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $18.00.
Get Our Latest Research Report on Mesoblast
Mesoblast Company Profile
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
